enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference [Yahoo! Finance]
enGene Holdings Inc. (ENGN)
Company Research
Source: Yahoo! Finance
pivotal results and a targeted BLA filing in H2 2026 aiming for approval in 2027, and the company reports more than $300 million in cash runway into late 2028. Detalimogene is a non-viral gene therapy positioned for community urology, with preliminary data showing about a 63% complete response (CR anytime) , asserted "best-in-class" tolerability, and simple storage/administration that fits clinic workflows. enGene says it has largely finished PPQ/validation batches and is preparing the CMC module while holding FDA designations (Fast Track, RMAT, CDRP), and plans a U.S. commercial field force of roughly 40–60 sales representatives with partnering planned for Europe and other regions. Interested in enGene Holdings Inc.? Here are five stocks we like better. enGene (NASDAQ:ENGN) CEO Ron Cooper said the company's focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive bladder ca
Show less
Read more
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of CarePR Newswire
- enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update [Yahoo! Finance]Yahoo! Finance
- enGene (ENGN) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ENGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold".MarketBeat
- enGene Holdings: Key Catalysts Incoming For 2026 [Seeking Alpha]Seeking Alpha
- enGene (ENGN) had its price target lowered by Oppenheimer Holdings, Inc. from $33.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
ENGN
Sec Filings
- 3/9/26 - Form S-8
- 3/9/26 - Form 424B5
- 3/9/26 - Form 8-K
- ENGN's page on the SEC website